Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1983 1
1984 2
1985 3
1986 3
1987 2
1988 4
1989 3
1990 6
1991 9
1992 5
1993 8
1994 12
1995 19
1996 19
1997 18
1998 24
1999 21
2000 27
2001 31
2002 41
2003 56
2004 67
2005 93
2006 98
2007 133
2008 126
2009 156
2010 175
2011 199
2012 257
2013 316
2014 315
2015 405
2016 431
2017 417
2018 461
2019 470
2020 458
2021 418
2022 315
2023 284
2024 457
2025 467
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,039 results

Results by year

Filters applied: . Clear all
Page 1
Prostate-specific oncogene OTUD6A promotes prostatic tumorigenesis via deubiquitinating and stabilizing c-Myc.
Peng Y, Liu J, Wang Z, Cui C, Zhang T, Zhang S, Gao P, Hou Z, Liu H, Guo J, Zhang J, Wen Y, Wei W, Zhang L, Liu J, Long J. Peng Y, et al. Cell Death Differ. 2022 Sep;29(9):1730-1743. doi: 10.1038/s41418-022-00960-x. Epub 2022 Feb 25. Cell Death Differ. 2022. PMID: 35217790 Free PMC article.
MYC drives the tumorigenesis of human cancers, including prostate cancer (PrCa), thus deubiquitinase (DUB) that maintains high level of c-Myc oncoprotein is a rational therapeutic target. Several ubiquitin-specific protease (USP) family members of DUB have been reported to …
MYC drives the tumorigenesis of human cancers, including prostate cancer (PrCa), thus deubiquitinase (DUB) that maintains high level of c …
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence.
Fu J, Su X, Li Z, Deng L, Liu X, Feng X, Peng J. Fu J, et al. Oncogene. 2021 Jul;40(28):4625-4651. doi: 10.1038/s41388-021-01863-w. Epub 2021 Jun 18. Oncogene. 2021. PMID: 34145400 Review.
This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor (HGF) /mesenchymal-epithelial transition factor (c-MET)) signaling pathway in cancers. ...Furthermore, we extensively illustrate the malignant biological behaviors of HGF/c- …
This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor (HGF) /mesenchymal-epithelial transition factor …
Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma.
Ai M, Ma H, He J, Xu F, Ming Y, Ye Z, Zheng Q, Luo D, Yang K, Li J, Nie C, Pu W, Peng Y. Ai M, et al. Eur J Med Chem. 2024 Dec 15;280:116978. doi: 10.1016/j.ejmech.2024.116978. Epub 2024 Oct 18. Eur J Med Chem. 2024. PMID: 39447458
However, targeted therapy against c-Myc remains challenging. Herein, by conjugating VH032 with an optimized DNA sequence that recognized c-Myc complex, we discovered oligonucleotide-based proteolysis targeting chimeras (PROTACs), termed as MP-16 and MP-17, which eff …
However, targeted therapy against c-Myc remains challenging. Herein, by conjugating VH032 with an optimized DNA sequence that recogni …
Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy.
Li H, Huang MH, Jiang JD, Peng ZG. Li H, et al. World J Gastroenterol. 2018 Dec 21;24(47):5297-5311. doi: 10.3748/wjg.v24.i47.5297. World J Gastroenterol. 2018. PMID: 30598575 Free PMC article. Review.
Hepatitis C virus (HCV) infection commonly causes progressive liver diseases that deteriorate from chronic inflammation to fibrosis, cirrhosis and even to hepatocellular carcinoma. ...
Hepatitis C virus (HCV) infection commonly causes progressive liver diseases that deteriorate from chronic inflammation to fibrosis, …
Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis.
Peng J, Qi S, Wang P, Li W, Liu C, Li F. Peng J, et al. Dis Markers. 2016;2016:6594016. doi: 10.1155/2016/6594016. Epub 2016 Mar 16. Dis Markers. 2016. PMID: 27069297 Free PMC article. Review.
Results showed that increasing malignancy resulted in elevated c-Met expression. The relationship between c-Met expression and clinicopathologic features was also evaluated. c-Met expression correlated with disease-free survival, lymph node involvement, and l …
Results showed that increasing malignancy resulted in elevated c-Met expression. The relationship between c-Met expression and …
The oncogene c-Jun impedes somatic cell reprogramming.
Liu J, Han Q, Peng T, Peng M, Wei B, Li D, Wang X, Yu S, Yang J, Cao S, Huang K, Hutchins AP, Liu H, Kuang J, Zhou Z, Chen J, Wu H, Guo L, Chen Y, Chen Y, Li X, Wu H, Liao B, He W, Song H, Yao H, Pan G, Chen J, Pei D. Liu J, et al. Nat Cell Biol. 2015 Jul;17(7):856-67. doi: 10.1038/ncb3193. Epub 2015 Jun 22. Nat Cell Biol. 2015. PMID: 26098572
Oncogenic transcription factors are known to mediate the conversion of somatic cells to tumour or induced pluripotent stem cells (iPSCs). Here we report c-Jun as a barrier for iPSC formation. c-Jun is expressed by and required for the proliferation of mouse embryoni …
Oncogenic transcription factors are known to mediate the conversion of somatic cells to tumour or induced pluripotent stem cells (iPSCs). He …
Cystatin C and intravenous thrombolysis.
Peng M, Chen Y, Geng G. Peng M, et al. Eur J Neurol. 2021 Apr;28(4):e28. doi: 10.1111/ene.14722. Epub 2021 Jan 22. Eur J Neurol. 2021. PMID: 33421235 No abstract available.
6,039 results